GB0625321D0 - Cancer biomarker - Google Patents

Cancer biomarker

Info

Publication number
GB0625321D0
GB0625321D0 GBGB0625321.5A GB0625321A GB0625321D0 GB 0625321 D0 GB0625321 D0 GB 0625321D0 GB 0625321 A GB0625321 A GB 0625321A GB 0625321 D0 GB0625321 D0 GB 0625321D0
Authority
GB
United Kingdom
Prior art keywords
cancer biomarker
biomarker
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0625321.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Surrey
Original Assignee
University of Surrey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Surrey filed Critical University of Surrey
Priority to GBGB0625321.5A priority Critical patent/GB0625321D0/en
Publication of GB0625321D0 publication Critical patent/GB0625321D0/en
Priority to GBGB0719792.4A priority patent/GB0719792D0/en
Priority to SI200731399T priority patent/SI2115472T1/sl
Priority to CN200780051417.9A priority patent/CN101675341B/zh
Priority to RU2009127774/15A priority patent/RU2460075C2/ru
Priority to ES07848631.3T priority patent/ES2445185T3/es
Priority to EP07848631.3A priority patent/EP2115472B1/en
Priority to DK07848631.3T priority patent/DK2115472T3/da
Priority to PL07848631T priority patent/PL2115472T3/pl
Priority to NZ577548A priority patent/NZ577548A/en
Priority to MX2009006378A priority patent/MX2009006378A/es
Priority to PCT/GB2007/004902 priority patent/WO2008075056A1/en
Priority to CA2671939A priority patent/CA2671939C/en
Priority to AU2007335999A priority patent/AU2007335999B2/en
Priority to PT78486313T priority patent/PT2115472E/pt
Priority to US12/518,708 priority patent/US8460882B2/en
Priority to JP2009542216A priority patent/JP5683108B2/ja
Priority to BRPI0720371A priority patent/BRPI0720371B8/pt
Priority to IL199241A priority patent/IL199241A/en
Priority to CY20141100091T priority patent/CY1115178T1/el
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
GBGB0625321.5A 2006-12-19 2006-12-19 Cancer biomarker Ceased GB0625321D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers
BRPI0720371A BRPI0720371B8 (pt) 2006-12-19 2007-12-19 métodos para diagnóstico ou monitoramento da progressão de câncer de próstata em um indivíduo e uso in vitro de pelo menos um homeodomínio contendo o fator de transcrição como um biomarcador para câncer de próstata
PL07848631T PL2115472T3 (pl) 2006-12-19 2007-12-19 Biomarkery nowotworowe
PCT/GB2007/004902 WO2008075056A1 (en) 2006-12-19 2007-12-19 Cancer biomarkers
RU2009127774/15A RU2460075C2 (ru) 2006-12-19 2007-12-19 Биомаркеры рака
ES07848631.3T ES2445185T3 (es) 2006-12-19 2007-12-19 Biomarcadores de cáncer
EP07848631.3A EP2115472B1 (en) 2006-12-19 2007-12-19 Cancer biomarkers
DK07848631.3T DK2115472T3 (da) 2006-12-19 2007-12-19 Cancerbiomarkører
SI200731399T SI2115472T1 (sl) 2006-12-19 2007-12-19 Biomarkerji raka
NZ577548A NZ577548A (en) 2006-12-19 2007-12-19 Cancer biomarkers
MX2009006378A MX2009006378A (es) 2006-12-19 2007-12-19 Biomarcadores para cancer.
CN200780051417.9A CN101675341B (zh) 2006-12-19 2007-12-19 癌症的生物标志物
CA2671939A CA2671939C (en) 2006-12-19 2007-12-19 Biomarker for detecting prostate cancer
AU2007335999A AU2007335999B2 (en) 2006-12-19 2007-12-19 Cancer biomarkers
PT78486313T PT2115472E (pt) 2006-12-19 2007-12-19 Biomarcadores de cancro
US12/518,708 US8460882B2 (en) 2006-12-19 2007-12-19 Cancer biomarkers
JP2009542216A JP5683108B2 (ja) 2006-12-19 2007-12-19 癌バイオマーカー
IL199241A IL199241A (en) 2006-12-19 2009-06-08 Cancer biomarkers
CY20141100091T CY1115178T1 (el) 2006-12-19 2014-02-05 Βιοδεικτες καρκινου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625321.5A GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers

Publications (1)

Publication Number Publication Date
GB0625321D0 true GB0625321D0 (en) 2007-01-24

Family

ID=39265269

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB0625321.5A Ceased GB0625321D0 (en) 2006-12-19 2006-12-19 Cancer biomarker
GBGB0719792.4A Ceased GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers

Family Applications After (1)

Application Number Title Priority Date Filing Date
GBGB0719792.4A Ceased GB0719792D0 (en) 2006-12-19 2007-10-10 Cancer biomarkers

Country Status (19)

Country Link
US (1) US8460882B2 (enExample)
EP (1) EP2115472B1 (enExample)
JP (1) JP5683108B2 (enExample)
CN (1) CN101675341B (enExample)
AU (1) AU2007335999B2 (enExample)
BR (1) BRPI0720371B8 (enExample)
CA (1) CA2671939C (enExample)
CY (1) CY1115178T1 (enExample)
DK (1) DK2115472T3 (enExample)
ES (1) ES2445185T3 (enExample)
GB (2) GB0625321D0 (enExample)
IL (1) IL199241A (enExample)
MX (1) MX2009006378A (enExample)
NZ (1) NZ577548A (enExample)
PL (1) PL2115472T3 (enExample)
PT (1) PT2115472E (enExample)
RU (1) RU2460075C2 (enExample)
SI (1) SI2115472T1 (enExample)
WO (1) WO2008075056A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
DE102006047617B4 (de) 2006-10-09 2008-11-27 Clariant International Limited Verfahren zur Herstellung basischer (Meth)acrylamide
DE102008017216B4 (de) 2008-04-04 2013-08-14 Clariant International Ltd. Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden
GB0823445D0 (en) * 2008-12-23 2009-01-28 Univ Surrey Biomarker
DE102009031059A1 (de) 2009-06-30 2011-01-05 Clariant International Ltd. Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen
GB0912175D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
GB0912190D0 (en) * 2009-07-13 2009-08-26 Univ Surrey Biomarker
US20120177672A1 (en) * 2009-07-13 2012-07-12 The University Of Surrey Therapeutic peptides, polypeptides and nucleic acid sequences
DE102009042522A1 (de) 2009-09-22 2011-04-07 Clariant International Ltd. Kontinuierliches Umesterungsverfahren
DE102009042523B4 (de) 2009-09-22 2012-02-16 Clariant International Ltd. Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen
GB0921329D0 (en) * 2009-12-04 2010-01-20 Univ Surrey Biomarker
DE102010056565A1 (de) 2010-12-30 2012-07-05 Clariant International Ltd. Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere
CA2835728A1 (en) * 2011-05-12 2012-11-15 Noviogendix Research B.V. Molecular markers in prostate cancer
US20140106363A1 (en) * 2011-05-12 2014-04-17 Noviogendix Research B.V. Molecular markers in prostate cancer
WO2013037118A1 (zh) * 2011-09-16 2013-03-21 上海长海医院 前列腺癌的生物学标志物、治疗靶点及其用途
JP5990274B2 (ja) * 2011-12-05 2016-09-07 ファイジェニクス インコーポレイテッド 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
US9110030B2 (en) 2012-06-29 2015-08-18 Daniel A. Kerschensteiner Colorimetric gelatinase assay
US10613087B2 (en) * 2012-08-10 2020-04-07 Analiza, Inc. Methods and devices for analyzing species to determine diseases
WO2014179959A1 (en) * 2013-05-09 2014-11-13 The Procter & Gamble Company Method and system for assessing health condition
WO2016102560A1 (en) * 2014-12-23 2016-06-30 The University Of Surrey Glycosylated biomarker
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3303616B1 (en) * 2015-05-29 2021-01-06 Koninklijke Philips N.V. Methods of prostate cancer prognosis
US20190247461A1 (en) * 2015-09-23 2019-08-15 Centre National De La Recherche Scientifique Homeoproteins for use in the treatment of neurodegenerative disorders
CN106282347A (zh) * 2016-08-17 2017-01-04 中南大学 HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用
WO2018119715A1 (zh) * 2016-12-28 2018-07-05 中国科学院广州生物医药与健康研究院 一种获得t细胞的方法及应用
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
KR101777259B1 (ko) * 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
KR101777254B1 (ko) 2017-07-14 2017-09-13 주식회사 무진메디 En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물
CN107727729A (zh) * 2017-11-22 2018-02-23 南宁科城汇信息科技有限公司 一种oa候选标志物诊断模型的建立方法
CN107894507A (zh) * 2017-11-22 2018-04-10 南宁科城汇信息科技有限公司 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法
KR101923199B1 (ko) 2018-04-25 2018-11-28 주식회사 무진메디 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물
CN111363817B (zh) * 2018-12-26 2024-02-02 广州康立明生物科技股份有限公司 基于hoxd12基因的肺癌诊断剂及试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999000498A1 (en) 1997-06-27 1999-01-07 Human Genome Sciences, Inc. Human nk-3 related prostate specific gene-1
RU2234942C2 (ru) * 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
CA2347081A1 (en) * 1998-10-19 2000-04-27 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating prostate cancer
EP1290442B1 (en) 2000-05-30 2013-11-13 Aarhus Universitet An assay method for testing plant material for exposure to herbicides using biomarkers
AU2001277521A1 (en) * 2000-06-30 2002-01-14 Epigenomics Ag Diagnosis of diseases associated with cell signalling
US20050079492A1 (en) * 2000-09-12 2005-04-14 Burgess Jr. Robert M. Micro-arrayed organization of transcription factor target genes
US20040063216A1 (en) 2000-12-24 2004-04-01 Iser Lubocki Method for detecting biomarkers
AU2002249834B2 (en) 2000-12-24 2008-05-22 Iser Lubocki A method for detecting biomarkers
DE60232059D1 (de) * 2001-03-01 2009-06-04 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
CA2469089A1 (en) * 2003-07-08 2005-01-08 Institut De Recherches Cliniques De Montreal En-2 gene, disgnostic and therapeutic uses thereof
US20060014301A1 (en) 2004-07-13 2006-01-19 Power3 Medical Products, Inc. Antibody-based system for detection of differential protein expression patterns
EP2284279A1 (en) * 2004-12-02 2011-02-16 Epigenomics AG Methods and nucleic acids for the analysis of gene expression associated with the prognosis of prostate cell proliferative disorders
US9416422B2 (en) * 2005-02-18 2016-08-16 Sloan-Kettering Institute For Cancer Research Methods for detecting minimum residual disease

Also Published As

Publication number Publication date
AU2007335999A1 (en) 2008-06-26
WO2008075056A1 (en) 2008-06-26
JP2010513901A (ja) 2010-04-30
CN101675341A (zh) 2010-03-17
IL199241A (en) 2014-03-31
BRPI0720371B8 (pt) 2021-07-27
US20100093558A1 (en) 2010-04-15
BRPI0720371A2 (pt) 2013-12-31
BRPI0720371B1 (pt) 2019-05-28
PL2115472T3 (pl) 2014-05-30
CN101675341B (zh) 2017-08-08
RU2009127774A (ru) 2011-01-27
CA2671939C (en) 2017-10-03
CA2671939A1 (en) 2008-06-26
MX2009006378A (es) 2009-08-24
CY1115178T1 (el) 2016-12-14
NZ577548A (en) 2012-03-30
EP2115472B1 (en) 2013-11-06
PT2115472E (pt) 2014-02-14
EP2115472A1 (en) 2009-11-11
DK2115472T3 (da) 2014-02-10
GB0719792D0 (en) 2007-11-21
AU2007335999B2 (en) 2013-09-05
JP5683108B2 (ja) 2015-03-11
SI2115472T1 (sl) 2014-05-30
US8460882B2 (en) 2013-06-11
ES2445185T3 (es) 2014-02-28
RU2460075C2 (ru) 2012-08-27

Similar Documents

Publication Publication Date Title
GB0719792D0 (en) Cancer biomarkers
EP2009738A4 (en) ANTENNA
IL190382A0 (en) Detecting prostate cancer
GB2436623B (en) Microtome
IL186980A0 (en) Characterizing prostate cancer
TWI340501B (en) Noise-supressing antenna assamblage
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
IL173251A0 (en) Multi purpose probe
GB0615902D0 (en) Antenna
GB0623160D0 (en) Biomolecules
GB0618127D0 (en) Biomarker
TWI329386B (en) Antenna
GB0618429D0 (en) Cancer test
GB0511302D0 (en) Biomarkers
EP2022500A4 (en) TUMOR SUPPRESSOR
GB0617605D0 (en) Biomarkers
GB2436166B (en) Liquid-coupled antenna
GB0720334D0 (en) Cancer biomarker
GB0620467D0 (en) Biomarker
GB0607710D0 (en) Biomarkers
GB0610030D0 (en) Biomarkers
GB0708064D0 (en) Biomarker
GB0617223D0 (en) Complex
GB0521360D0 (en) Biomarker
AU3514P (en) ARCBENT Arctotis fastuosa

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)